首页> 美国卫生研究院文献>Cancer Science >l‐β‐D‐Arabinofuranosylcytosine Is Cytotoxic in Quiescent Normal Lymphocytes Undergoing DNA Excision Repair
【2h】

l‐β‐D‐Arabinofuranosylcytosine Is Cytotoxic in Quiescent Normal Lymphocytes Undergoing DNA Excision Repair

机译:l-β-D-阿拉伯呋喃糖胞嘧啶在接受DNA切除修复的静态正常淋巴细胞中具有细胞毒性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have sought to clarify the potential activity of the S‐phase‐specific antileukemic agent 1‐β‐D‐arabinofuranosylcytosine (ara‐C), an inhibitor of DNA synthesis, in quiescent cells that are substantially non‐sensitive to nucleoside analogues. It was hypothesized that the combination of ara‐C with DNA damaging agents that initiate DNA repair will expand ara‐C cytotoxicity to non‐cycling cells. The repair kinetics, which included incision of damaged DNA, gap‐filling by DNA synthesis and rejoining by ligation, were evaluated using the single cell gel electrophoresis (Comet) assay and the thymidine incorporation assay. When normal lymphocytes were treated with ultraviolet C or with l,3‐bis(2‐chloroethyl)‐1‐nitrosourea (BCNU), the processes of DNA excision repair were promptly initiated and rapidly completed. When the cells were incubated with ara‐C prior to irradiation or BCNU treatment, the steps of DNA synthesis and rejoining in the repair processes were both inhibited. The ara‐C‐mediated inhibition of the repair processes was concentration‐dependent, with the effect peaking at 10 μM. The combination of ara‐C with these DNA repair initiators exerted subsequent cytotoxicity, which was proportional to the extent of the repair inhibition in the presence of ara‐C. In conclusion, ara‐C was cytotoxic in quiescent cells undergoing DNA repair. This might be attributed to unrepaired DNA damage that remained in the cells, thereby inducing lethal cytotoxicity. Alternatively, ara‐C might exert its own cytotoxicity by inhibiting DNA synthesis in the repair processes. Such a strategy may be effective against a dormant subpopulation in acute leukemia that survives chemotherapy.
机译:我们试图澄清S期特异性抗白血病药物1-β-D-阿拉伯呋喃糖基胞嘧啶(ara-C)(一种DNA合成抑制剂)在对核苷类似物基本不敏感的静态细胞中的潜在活性。据推测,araC与DNA损伤剂的结合将启动DNA修复,将araC细胞毒性扩展至非循环细胞。使用单细胞凝胶电泳(Comet)分析法和胸苷掺入分析法评估了修复动力学,包括切割受损的DNA,通过DNA合成填补缺口并通过连接重新结合。当用紫外线C或1,3-二(2-氯乙基)-1-亚硝基脲(BCNU)处理正常淋巴细胞时,DNA切除修复的过程迅速开始并迅速完成。当细胞在辐射或BCNU处理之前与ara‐C孵育时,DN​​A合成步骤和修复过程中的重新结合均受到抑制。 araC介导的修复过程抑制是浓度依赖性的,其作用在10μM时达到峰值。 araC与这些DNA修复引发剂的组合会产生随后的细胞毒性,这与存在araC时修复抑制的程度成正比。总之,ara‐C在接受DNA修复的静态细胞中具有细胞毒性。这可能归因于保留在细胞中的未修复的DNA损伤,从而诱导了致命的细胞毒性。另外,araC可能通过在修复过程中抑制DNA合成来发挥自身的细胞毒性。这种策略可能有效地抵抗了在化疗后幸存的急性白血病中的休眠亚群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号